Annual Report 2024-25
Awaiting price reaction for this filing.
Citurgia Biochemicals Ltd submitted its 50th Annual Report for FY2024-25. The company reported zero revenue and a net loss of Rs. 42.30 lakhs, slightly improved from a loss of Rs. 47.55 lakhs in the previous year. EPS stood at (Rs. 0.160). Operations at its calcium carbonate division in Uttarakhand remained suspended throughout the year due to lack of working capital and pending environmental clearance. The BIFR Rehabilitation Scheme is stayed by the Uttarakhand High Court, and the company's appeal is pending before the Supreme Court. No dividend was recommended due to accumulated losses.
This is a deeply distressed, operationally dormant company with no revenue and no clear path to restart. Shareholders face continued uncertainty until environmental clearance and Supreme Court matters are resolved. Notably, BSE granted in-principle approval for revocation of trading suspension (suspended since Jan 2013) and approved promoter reclassification, which are positive structural developments but do not address the fundamental business viability concerns.